Antibiotics: Natural products essential to human health

Medicinal Research Reviews

Volumn 29, Issue 6, 2009, Pages 821-842

  Demain, Arnold L ^a  

^a DREW UNIVERSITY   (United States)

Author keywords

lactams; Antibiotics; Glycopeptides; Lipopeptides; Macrolides; Natural products; Resistance development; Tetracyclines

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALKALOID; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANSAMYCIN DERIVATIVE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; ANTIPARASITIC AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CARBAPENEM DERIVATIVE; CEPHALOSPORIN DERIVATIVE; CLARITHROMYCIN; CYTARABINE; CYTOSTAR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROMYCIN; MACROLIDE; NATURAL PRODUCT; PENICILLIN DERIVATIVE; POLYENE ANTIBIOTIC AGENT; POLYKETIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SALICYLIC ACID DERIVATIVE; TETRACYCLINE; TETRACYCLINE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; BIOTECHNOLOGY; COST BENEFIT ANALYSIS; DRUG APPROVAL; DRUG ISOLATION; DRUG MARKETING; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; ENTEROCOCCAL INFECTION; HERPES VIRUS INFECTION; HOSPITAL INFECTION; HUMAN; INFECTION; METABOLITE; NONHODGKIN LYMPHOMA; NONHUMAN; PATHOGENESIS; REVIEW;

ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; HUMANS; MICROBIOLOGY; PLANTS;

EID: 70350448473     PISSN: 01986325     EISSN: None     Source Type: Journal    
DOI: 10.1002/med.20154     Document Type: Review

References (154)

1. Nicolaou KC, Montagnon T. Molecules that changed the world. Weinheim, Germany: Wiley-VCH; 2008.
2. Verdine GL. The combinatorial chemistry of nature. Nature 1996;384:11-13.
3. Mendelson R, Balick MJ. The value of undiscovered pharmaceuticals in tropical forests. Econ Bot 1995;49:223-228.
4. Berdy J. Bioactive microbial metabolites. A personal view. J Antibiot 2005;58:1-26. (Pubitemid 40299637)
5. Dictionary of Natural Products. Chapman & Hall: CRC Press; 2001.
6. Henkel T, Brunne RM, Müller H, Reichel F. Statistical investigation into the structural complementarity of natural products and synthetic compounds. Angew Chem Int Ed Engl 1999;38:643-647. (Pubitemid 29129819)
7. Knight V, Sanglier JJ, DiTullio D, et al. Diversifying microbial natural products for drug discovery. Appl Microbiol Biotechnol 2003;62:446-458. (Pubitemid 37372436)
8. Fenical W, Jensen PR. Marine microorganisms: A new biomedical resource. In: Attaway DH, Zaborsky OR, editors. Marine biotechnology I: Pharmaceutical and bioactive natural products. New York: Plenum; 1993. pp 419-475.
9. Berdy J. Are actinomycetes exhausted as a source of secondary metabolites? In: Proceedings of the 9th International Symposium on the Biology of the Actinomycetes; Part 1. New York: Allerton Press; 1995. pp 3-23.
10. Roessner CA, Scott AI. Genetically engineered synthesis of natural products: From alkaloids to corrins. Ann Rev Microbiol 1996;50:467-490.
11. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prods 2003;66:1022-1037.
12. Newman DJ, Cragg GM. Natural products as sources of new drugs over the last 25 years. J Nat Prods 2007;70:461-477.
13. Holland HD. Evidence for life on earth more than 3850 million years ago. Science 1998;275:38-39.
14. Verpoorte R, van der Heijden R, ten Hoopen HJG, Memelink J. Metabolic engineering of plant secondary metabolite pathways for the production of fine chemicals. Biotechnol Lett 1999;21:467-479.
15. Ondetti MA, Williams NJ, Sabo EF, Pluscec J, Weaver ER, Kocy O. Angiotensin-converting enzyme inhibitors from the venom of Bothrops jaraca. Isolation, elucidation of structure, and synthesis. Biochemistry 1971;10:4033-4039.
16. Patchett AA. Alfred Burger award address in medicinal chemistry. Natural products and design: Interrelated approaches in drug discovery. J Med Chem 2002;45:5609-5616.
17. Andermann AAJ. Physicians, fads and pharmaceuticals: A history of aspirin. McGill J Med 1996;115-120.
18. Kiefer DM. A century of pain relief. Todays Chem Work 1997;6:38-42.
19. Jaffe EE. Hoffmann or Eichengrin? Chem Heritage 2003;21:4.
20. Rayl AJS. Oceans: Medicine chests of the future? Scientist 1999;13:1,4.
21. Yang SS, Cragg GM, Newman DJ, Bader JP. Natural product-based anti-HIV drug discovery and development facilitated by the NCI development therapeutics program. J Nat Prods 2001;64:265-277.
22. Overbye KM, Barrett J. Antibiotics: Where did we go wrong? Drug Disc Today 2005;10:45-52.
23. Topliss JG, Clark AM, Ernst E, Hufford CD, Johnston GAR, Rimoldi JM, Weimann BJ. Natural and synthetic substances related to human health. Pure Appl Chem 2002;74:1957-1985.
24. Verpoorte R. Pharmacognosy in the new millennium: Lead finding and biotechnology. J. Pharm Pharmacol 2000;52:253-262. (Pubitemid 30189379)
25. Raskin I, et al. Plants and human health in the twentieth century. Trends Biotechnol 2002;20:522-531. (Pubitemid 35356407)
26. Rawls RL. Polyketides: Research increases on modular synthesis of these biomolecules by enzymes. Chem Eng News 1998;76:29-30.
27. Xue Q, Ashley G, Hutchinson CR, Santi DV. A multi-plasmid approach to preparing large libraries of polyketides. Proc Natl Acad Sci USA 1999;96:11740-11745. (Pubitemid 29502802)
28. Cerda-Olmedo E. The genetics of chemical diversity. Crit Revs Microbiol 1994;20:151-160.
29. Brueckner B, Blechschmidt D, Sembdner G, Schneider G. Fungal gibberellin production. In: Vandamme EJ, editor. Biotechnology of vitamins, pigments and growth factors. London, UK: Elsevier Applied Science; 1989. pp 383-429.
30. Mander LN. The chemistry of gibberellins, an overview. Chem Revs 1992;92:573-612.
31. American Academy of Microbiology colloquium. Microbiology in the 21st Century: Where Are We and Where Are We Going? 2004.
32. Hölke U, Höfer M, Lenz J. Biotechnical advantages of laboratory-scale solid-state fermentation with fungi. Appl Microbiol Biotechnol 2004;64:175-186. (Pubitemid 38559067)
33. Kieser T, Bibb MJ, Buttner MJ, Chater KF, Hopwood DA. Practical streptomyces genetics. Norwich UK: The John Innes Foundation; 2000.
34. Liu X-H, Zhao L-B, She Z-G, Lin YC. Recent progress in bioactive metabolites of marine microorganisms. Chi J Antibiot 2004;29:492-510. (Pubitemid 39390271)
35. Piel J, Hui D, Wen G, Butzke D, Platzer M, Fusetani N, Matsunaga S. Antitumor polyketide biosynthesis by an uncultivated bacterial symbiont of the marine sponge Theonella swinhoei. Proc Natl Acad Sci USA 2004;101:16222-16227. (Pubitemid 39552826)
36. Bode HB, Bethe B, Hofs R, Zeeck A. Big effects from small changes: Possible ways to explore nature's chemical diversity. Chembiochem 2002;3:619-627. (Pubitemid 36004525)
37. Schiewe H-J, Zeeck A. Cineromycins: Butyrolactones and ansamycins of the secondary metabolite pattern created by a single strain of Streptomyces. J Antibiot 1999;52:635-642. (Pubitemid 29378221)
38. Hardt IH, Steinmetz H, Gerth K, Sasse F, Reichenbach H, Höfle G. New natural epothilones from Sorangium cellulosum, Strains So ce90/B2 and So ce90/D13: Isolation, structural elucidation, and SAR studies. J Nat Prods 2001;64:847-856. (Pubitemid 32729891)
39. Bok JW, Hoffmeister D, Maggio-Hall LA, Murillo R, Glasner JD, Keller NP. Genomic mining for Aspergillus natural products. Chem Biol 2006;13:31-37. (Pubitemid 43099922)
40. Busti E, Monciardini P, Cavaletti L, Bamonte R, Lazzarini A, Sosio M, Donadio S. Antibiotic-producing ability by representatives of a newly discovered lineage of actinomycetes. Microbiology 2006;152:675-683.
41. Staunton J. Combinitorial biosynthesis of erythromycin and complex polyketides. Curr Opin Chem Biol 1998;2:339-345. (Pubitemid 128423237)
42. Clark AM. Natural products as a resource for new drugs. Pharmaceut Res 1996;13:1133-1141. (Pubitemid 26279315)
43. Hutchinson CR. Antibiotics from genetically engineered microorganisms. In: Strohl W, editor. Biotechnology of antibiotics, 2nd edition. New York: Marcel Dekker; 1997. pp 683-702.
44. McAlpine J. Unnatural natural products by genetic manipulation. In: Sapienza DM, Savage LM, editors. Natural products II: New technologies to increase efficiency and speed. Southborough MA: Internat Bus Comm; 1998. pp 251-278.
45. Vicente M, Chater K, de Lorenzo V. Bacterial transcription factors involved in global regulation. Molec Microbiol 1999;33:8-17. (Pubitemid 29304184)
46. Dykhuizen DE. Santa Rosalia revisited: Why are there so many species of bacteria? Ant v Leeuwenhoek 1998;73:25-33.
47. Torsvik V, Sorheim R, Goksoyr J. Total bacterial diversity in soil and sediment communities - A review. J Indust Microbiol 1996;17:170-178. (Pubitemid 27061875)
48. Carlisle MJ. The success of the hypha and mycelium. In: Gow NAR, Gadd GM, editors. The growing fungus. London: Chapman & Hall;1995. pp 1-18.
49. Hawksworth DL. The fungal dimension of biodiversity: Magnitude, significance, and conservation. Mycol Res 1991;95:641-655.
50. Selitrennikoff CP. Antifungal proteins. Appl Environ Microbiol 2001;67:2883-2894.
51. Möller C, Weber G, Dreyfuss MM. Intraspecific diversity in the fungal species Chaunopycnis alba: Implications for microbial screening programs. J Ind Microbiol 1996;17:359-372. (Pubitemid 27064581)
52. Bull AT, Ward AC, Goodfellow M. Search and discovery strategies for biotechnology: The paradigm shift. Microbiol Mol Biol Rev 2000;64:573-606. (Pubitemid 30688766)
53. Lam KS. New aspects of natural products in drug discovery. Trends Microbiol 2007;15:279-289. (Pubitemid 46856162)
54. Yoneyama H, Katsumata R. Antibiotic resistance in bacteria and its future for novel antibiotic development. Biosci Biotechnol Biochem 2006;70:1060-1075. (Pubitemid 43765235)
55. Nathan C. Antibiotics at the crossroads. Nature 2004;431:899-902.
56. Lederberg J. Pathways of discovery: Infectious history. Science 2000;288:287-293.
57. Strohl W. Industrial antibiotics: Today and the future. In: Strohl W, editor. Biotechnology of antibiotics, 2nd edition. NewYork: Marcel Dekker; 1997. pp 1-47.
58. Bronson JJ, Barrett JF. Quinolone, everninomycin, glycylcycline, carbapenem, lipopeptide and cephem antibiotics in clinical development. Curr Med Chem 2001;8:1775-1793.
59. Erdmann J. Bacteria resistant to drugs draw scrutiny of biofirms. Gen Eng News 1999;19:1,19,50,58.
60. Projan SJ, Youngman PJ. Antimicrobials: New solutions badly needed. Curr Opin Microbiol 2002;5:463-465.
61. Hranueli D, Cullum J, Basrak B, Goldstein P, Long PF. Plasticity of the Streptomyces genome-evolution and engineering of new antibiotics. Curr Med Chem 2005;12:1697-1704. (Pubitemid 40895009)
62. Connors N, Pollard D. Pneumocandin B0 production by fermentation of the fungus Glarea lozoyensis: Physiological and engineering factors affecting titer and structural analogue formation. In: An Z, editor. Handbook of industrial mycology. New York: Marcel Dekker; 2004. pp 515-538.
63. Georgopapadakou NH. Antifungals: Mechanism of action and resistance, established and novel drugs. Curr Opin Microbiol 1998;1:547-557.
64. Wilson JF. Renewing the fight against bacteria. Scientist 2002;16:22-23.
65. Strohl WR. Antimicrobials. In: Bull AT, editor. Microbial diversity and bioprospecting. Washington, DC: ASM Press; 2004. pp 336-355.
66. Elander RP. Industrial production of β-lactam antibiotics. Appl Microbiol Biotechnol 2003;61:385-392.
67. Schmitt EK, Bunse A, Janus D, Hoff B, Friedlin E, Kürnsteiner H, Kück U. Winged Helix Transcription factor CPCR1 is involved in regulation of β-lactam biosynthesis in the fungus Acremonium chrysogenum. Eukaryotic Cell 2004;3:121-134. (Pubitemid 38237304)
68. Robin J, Lettier G, McIntyre M, Noorman H, Nielsen J. Continuous cultivations of Penicillium chrysogenum strain expressing the expandase gene from Streptomyces clavuligerus: Growth yields and morphological characterisation. Biotechnol Bioeng 2003;83:353-360. (Pubitemid 36818436)
69. Coulthurst SJ, Barnard AML, Salmond GPC. Regulation and biosynthesis of carbapenem antibiotics in bacteria. Nature Rev Microbiol 2005;1:295-306.
70. Kahan FS, Kahan FM, Goegelman RT, Currie SA, Jackson M, Stapley EO, Miller TW, Miller AK, Hendlin D, Mochales S, Hernandez S, Woodruff HB, Birnbaum J. Thienamycin, a new β-lactam antibiotic. I. Discovery, taxonomy, isolation, and physical properties. J Antibiot 3 1979;2:1-12.
71. Vaara M. Antibiotic-supersusceptible mutants of Escherichia coli and Salmonella typhimurium. Antimicrob Agents Chemother 1993;37:2255-2260. (Pubitemid 23324440)
72. Nikaido H. Multidrug efflux pumps of Gram-negative bacteria. J Bacteriol 1996;178:5819-5853. (Pubitemid 26337766)
73. Lewis K. Multidrug resistance pumps in bacteria: Variations on a theme. TIBS 1994;19:119-123. (Pubitemid 24082789)
74. Petkovic H, Cullum J, Hranueli D, Hunter IS, Peric-Concha N, Pigac J, Thamchaipenet A, Vujaklija D, Long PF. Genetics of Streptomyces rimosus, the oxytetracycline producer. Microbiol Mol Biol Rev 2006;70:704-728. (Pubitemid 44484690)
75. Minas W. Production of erythromycin with Saccharopolyspora erythraea. In: Barredo JL, editor. Microbial processes and products. Totowa, NJ: Humana Press; 2004. pp 65-89.
76. Fleming ID, Nisbet LJ, Brewer SJ. Target directed antimicrobial screens. In: Bu'lock JD, Nisbet LJ, Winstanley DJ, editors. Bioactive microbial products: Search and discovery. London, UK: Academic Press; 1982. pp 107-130.
77. Woodruff HB, Hernandez S, Stapley ED. Evolution of antibiotic screening programme. Hindustan Antibiot Bull 1979;21:71-84.
78. Woodruff HB, McDaniel LE. Antibiotic approach in strategy of chemotherapy. Soc Gen Microbiol Symp 1958;8:29-48.
79. Gloer G. Applications of fungal ecology in the search for new bioactive natural products. In: Kubicek CP, Druzhinina IS, editors. The mycota IV environmental and microbial relationships, 2nd edition. New York: Springer; 2007. pp 257-283.
80. Brennan MB. Drug discovery: Filtering out failures early in the game. Chem Eng News 2000;78:63-74.
81. Jones CG, Firn RD. On the evolution of plant secondary chemical diversity. Phil Trans R Soc 1991;333:273-280.
82. DiMasi J, Seibring M, Lasagna L. New drug development in the United States from 1963 to 1992. Clin Pharmacol Ther 1994;55:609-622.
83. Sader HS, Gales A. Emerging strategies in infectious diseases: New carbapenem and trinem antibacterial agents. Drugs 2001;61:553-564. (Pubitemid 32453367)
84. Lederberg J. Getting in tune with the enemy-microbes. Scientist 2003;17:20-21.
85. Singh SB, Barrett JF. Empirical antibacterial drug discovery-foundation in natural products. Biochem Pharmacol 2006;71:1006-1015. (Pubitemid 43306793)
86. DaSilva E, Iaccarino M. Emerging diseases: A global threat. Biotech Adv 1999;17:363-384.
87. Tenover FC, Hughes JM. The challenges of emerging infectious diseases. J Amer Med Assoc 1996;275:300-304.
88. Levin BR, Bonten MJM. Cycling antibiotics may not be good for your health. Proc Natl Acad Sci USA 2004;101:13101-13102.
89. Balaban N, Dell'Acqua G. Barriers on the road to new antibiotics. Scientist 2005;19:42-43.
90. Johnston N. Debaffling biofilms. Scientist 2004;18:34-35.
91. Sauer K, Camper AK, Garth D, Ehrlich D, Costerton JW, Davies DG. Pseudomonas aeruginosa displays multiple phenotypes during development as a biofilm. J Bacteriol 2002;184:1140-1154. (Pubitemid 34113383)
92. Stephens C, Shapiro L. Bacterial protein secretion - A target for new antibiotics? Chem Biol 1997;4:637-641.
93. Chu DT, Plattner JJ, Katz L. New directions in antibacterial research. J Med Chem 1996;39:3853-3874.
94. Morris A, Kellner JD, Low DE. The superbugs: Evolution, dissemination and fitness. Curr Opin Microbiol 1998;1:524-529.
95. Breiman R, Butler J, Tenover F, Elliot J, Facklam R. Emergence of drug-resistant pneumococcal infections in the United States. J Amer Med Assoc 1994;271:1831-1835. (Pubitemid 24169696)
96. Goldman DA, Weinstein RA, Wenzel RP, Tablan OC, Duma RJ, Gaynes RP, Schlosser J, Martone WJ. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals. J Amer Med Assoc 1996;275:234-240.
97. Moellering RC. The spectre of glycopeptide resistance: Current trends and future considerations. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 1997.
98. Leclercq R, Courvalin P. Resistance to glycopeptides in enterococci. Clin Inf Dis 1997;24:545-555.
99. Perichon B, Reynolds P, Courvalin P. VanD-type glycopeptide-resistant Entercoccus faecium BM4339. Antimicrob Agents Chemother 1997;41:2016-2018. (Pubitemid 27383248)
100. Thompson GA, Smith JA, Kenny MT, Dulwoeth JK, Kulmala HK, Yuh L. Pharmakinetics of teicoplanin upon multiple dose administration to normal healthy male volunteers. Biopharm Drug Dispos 1992;33:213-220.
101. Wood MJ. The comparative efficacy and safety of teicoplanin and vancomycin. J Antimicrob Chemother 1996;37:209-222. (Pubitemid 26123160)
102. Levy SB, Marshall B. Antibacterial resistance worldwide: Causes, challenges and responses. Nat Med Suppl 2004;10:S122-S129. (Pubitemid 40018235)
103. Leadbetter MR, et al. Hydrophobic vancomycin derivatives with improved ADME properties: Discovery of telavancin (TD-6424). J Antibiot 2004;57:326-336.
104. Boneca IG, Chios G. Vancomycin resistance: Occurrence, mechanisms and strategies to combat it. Expert Opin Ther Targets 2003;7:311-328. (Pubitemid 36722218)
105. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Invest Drugs 2007;16:717-733. (Pubitemid 46723274)
106. Wright GD. Resisting resistance: New chemical strategies for battling superbugs. Chem Biol 2000;7:R127-R132.
107. Stermitz FR, Lorenz P, Tawara JN, Zenewicz LA, Lewis K. Synergy in a medicinal plant: Antimicrobial action of berberine potentiated by 50-methoxyhydrocarpin, a multidrug pump inhibitor. Proc Natl Acad Sci USA 2000;97:1433-1437. (Pubitemid 30118458)
108. Silver LL. Multi-targeting by monotherapeutic antibacterials. Nature Revs Drug Disc 2007;6:41-55.
109. Berdy J. Recent developments of antibiotic research and classification of antibiotics according to chemical structure. Adv Appl Microbiol 1974;18:309-406.
110. Barriere JC, Berthaud N, Beyer D, Dutka-Malen S, Paris JM, Desnottes JF. Recent developments in streptogramin research. Curr Pharm Des 1998;4:155-180.
111. Nichterlein T, Kretschmar M, Hof H. RP 59500, a streptogramin derivative, is effective in murine listerosis. J Chemother 1996;8:107-112. (Pubitemid 26127819)
112. Moellering RC. Quinupristin/dalfopristin: Therapeutic potential for vancomycin-resistant enterococcal infections. J Antimicrob Chemother 1999;44:25-30.
113. Moellering RC, Linden PK, Reinhardt J, Blumberg EA, Bompart F, Talbot GH. The efficacy and safety of quinupristin/dalfopristin for the treatment of infections caused by vancomycin-resistant Enterococcus faecium. J Antimicrob Chemother 1999;44:251-261. (Pubitemid 29389289)
114. Stinson SC. Drug firms restock antibacterial arsenal. Chem & Eng News 1996;74:75-100.
115. Livermore DM. Quinopristin/dalfopristin and linezolid: Where, when, which and whether to use? J Antimicrob Chemother 2000;46:347-350.
116. Cimons M. FDA approves the antibiotic Synercid for limited clinical uses. ASM News 1999;65:800-801.
117. Sum P-E, Sum F-W, Projan SJ. Recent developments in tetracycline antibiotics. Curr Pharm Des 1998;4:119-132.
118. Petersen PJ, Jacobus NV, Weiss WJ, Sum PE, Testa RT. In vitro and in vivo antibacterial activities of a novel glycylcycline, the 9-t-butylglycylamido derivative of minocycline (GAR-936). Antimicrob Agents Chemother 1999;43:738-744.
119. Livermore DM. Tigecycline: What is it, and where should it be used? J Antimicrob Chemother 2005;56:611-614.
120. Dougherty TJ, Barrett JF. ABT-773: A new ketolide antibiotic. Expert Opin Invest Drugs 2001;10:343-351.
121. Henninger TC. Recent progress in the field of macrolide antibiotics. Expert Opin Ther Patents 2003;13:787-805. (Pubitemid 36748944)
122. Agouridas C, Denis A, Auger J-M, Benedetti Y, Bonnefoy A, Bretin F, Chantot J-F, Dussarat A, Fromentin C, Gouin D'Ambrieres S, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessit N. Synthesis and antibacterial activity of ketolides (6-O-methyl-3-oxoerythromycin derivatives): A new class of antibacterials highly potent against macrolide-resistant and -susceptible respiratory pathogens. J Med Chem 1998;41:4080-4100. (Pubitemid 28483484)
123. Kaneko T, McArthur H, Sutcliffe J. Recent developments in the area of macrolide antibiotics. Expert Opin Ther Patents 2000;10:403-425. (Pubitemid 30168869)
124. Yassin HM, Dever LL. Telithromycin: A new ketolide antimicrobial for treatment of respiratory tract infections. Expert Opin Invest Drugs 2001;10:353-367. (Pubitemid 32117943)
125. Denis A, Agouridas C, Auger J-M, Benedetti Y, Bonnefoy A, Bretin F, Chantot J-F, Dussarat A, Fromentin C, Gouin D'Ambrieres S, Lachaud S, Laurin P, Le Martret O, Loyau V, Tessit N, Pejac J-M, Perron S. Synthesis and antibacterial activity of HMR 3647, a new ketolide highly potent against erythromycin-resistant and susceptible pathogens. Bioorg Med Chem Lett 1999;9:3075-3080. (Pubitemid 29515385)
126. Leclercq R. Overcoming antimicrobial resistance: Profile of a new ketolide antibacterial, telithromycin. J Antimicrob Chemother 2001;48:9-23. (Pubitemid 33040683)
127. Bax R, Mullan N, Verhoef J. The millennium bugs - the need for and development of new antibacterials. J Antimicrob Agents 2000;16:51-59. (Pubitemid 30665425)
128. Borman S. Polyketide system cloned, characterized. Chem Eng News 1998;76:27-28.
129. Lynch AS. Efflux systems in bacterial pathogens: An opportunity for therapeutic intervention? An industry view. Biochem Pharamacol 2006;71:949-956.
130. Tally FP, Zeckel M, Wasilewski MM, Carini C, Berman CL, Drusano GL, Oleson Jr FB. Daptomycin: A novel agent for gram-positive infections. Expert Opin Invest Drugs 1999;8:1223-1238. (Pubitemid 29410579)
131. Baltz RH, Miao V, Wrigley SK. Natural products to drugs: Daptomycin and related lipopeptide antibiotics. Nat Prod Rep 2005;22:717-741. (Pubitemid 41830839)
132. Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Invest Drugs 2004;13:1159-1169. (Pubitemid 39242739)
133. Raja A, LaBonte J, Lebbos J, Kirkpatrick P. Daptomycin. Nature Rev/Drug Disc 2003;2:943-944.
134. Heinemann B, Kaplan MA, Hooper IR. Amphomycin and its production and recovery. US Patent 3,126,317. Filed November 20, 1958. Published March 24, 1964.
135. Malabarba A, Ciabatti R. Glycopeptide derivatives. Curr Med Chem 2001;8:1759-1773.
136. Ge M, Chen Z, Russell HO, Kohler J, Silver LL, Kerns R, Fukuzawa S, Thompson C, Kahne D. Vancomycin derivatives that inhibit peptidoglycan biosynthesis without binding D-Ala-D-Ala. Science 1999;284:507-511. (Pubitemid 29289628)
137. Walsh C. Deconstructing vancomycin. Science 1999;284:442-443.
138. Ciabatti R, Kettenring JK, Winters G, Tuan G, Zerilli L, Cavalleri B. Ramoplanin (A-16686), a new glycolipodepsipeptide antibiotic. III. Structure elucidation. J Antibiot 1989;41:254-267. (Pubitemid 19068323)
139. Cavalleri B, Pagani H, Volpe G, Selva E, Parenti F. A-16686, a new antibiotic from Actinoplanes. I. Fermentation, isolation and preliminary physiochemical characteristics. J Antibiot 1984;37:309-317.
140. Jiang W, Wanner J, Lee RJ, Bounaud P-Y, Boger DL. Total synthesis of the ramoplanin A2 and ramoplanose aglycon. J Amer Chem Soc 2002;124:5288-5290. (Pubitemid 34506924)
141. Cudic P, Behenna DC, Kranz JK, Kruger RG, Wand AJ, Veklich YI, Weisel JW, McCafferty DG. Functional analysis of lipoglycodepsipeptide antibiotic ramoplanin. Chem Biol 2002;9:897-906. (Pubitemid 35240909)
142. Paladino JA. Linezolid: An oxazolidinone antibacterial agent. Amer J Health Syst Pharm 2002;59:2413-2425.
143. Fox S, Farr-Jones S, Yund MA. New directions in drug discovery. Gen Eng News 1999;19:10,36,56,66,80.
144. Gadwood RC, Shinabarger DA. Progress in the oxazolidinone antibacterials. Ann Repts Med Chem 2000;35:135-144.
145. Diekema DJ, Jones RN. Oxazolidinones: A review. Drugs 2000;59:7-16.
146. Tally FA, Wendler PA, Houman F. Translation targets for antifungal drug development. Abstracts S5, 5th International Conference on Biotechnology and Microbial Products: Novel Pharmacol Agrobiol Act., Williamsburg 1997:19.
147. White TC. Antifungal drug resistance in Candida albicans. ASM News 1997;63:427-433.
148. Alexander BP, Perfect JR. Antifungal resistance trends towards the year 2000. Implications for therapy and new approaches. Drugs 1997;54:657-678.
149. DiDomenico B. Novel antifungal drugs. Curr Opin Microbiol 1999;2:509-515.
150. Schwartz RE, Sesin DF, Joshua H, Wilson KE, Kempf AJ, Goklen KA, Kuehner D, Gailliot P, Gleason C, White R, Inamine E, Bills G, Salmon P, Zitano L. Pneumocandins from Zalerion arboricola I. Discovery and isolation. J Antibiot 1992;45:1853-1866. (Pubitemid 23059697)
151. Kurtz MB. New antifungal drug targets: A vision for the future. ASM News 1998;64:31-39.
152. Hoang AT. Caspofungin acetate: An antifungal agent. Amer J Health-Syst Pharm 2001;58:1206-1214.
153. Georgopapadakou NH. Update on antifungals targeted to the cell wall: Focus on β-1,3-glucan synthase inhibitors. Expert Opin Invest Drugs 2001;10:269-280.
154. Debono M. The echinocandins: Antifungals targeted to the fungal cell wall. Expert Opin Invest Drugs 1994;3:821-829. (Pubitemid 24247049)